Gene and Cell Therapy – Products

Explore our new AAV Titer ELISA and AAV Antibody Assay Kits, designed for exceptional specificity, sensitivity, and accuracy to elevate your gene therapy research.

This report explores the latest trends driving biopharma innovation, highlighting areas including RNA therapy, bispecific drug development and advanced biologics.

This whitepaper explores how AAV titration and anti-AAV antibody ELISA kits streamline AAV-based gene therapy research, enhancing patient stratification, optimizing preclinical studies and supporting regulatory compliance.

Thermo Fisher Scientific has introduced the Invitrogen Vivofectamine™ Delivery Solutions to provide high-performance lipid nanoparticles (LNP) technology for non-viral delivery of nucleic acids.

BioPharmaSpec has officially announced three new European facilities. The new facilities will focus on discovery and R&D services, offering structural and physicochemical characterization services for a wide variety of biopharmaceutical products.

This whitepaper explores innovative approaches to achieving higher yields and stability, ensuring a seamless transition from lab to large-scale manufacturing.

SEKISUI Diagnostics’ microbial CDMO business announces it has completed construction of its £15.7 million ($20.7 million) cGMP capacity expansion at its UK site for clinical-grade drug substance manufacturing.

Terumo Blood and Cell Technologies ("Terumo BCT"), held a localization launch ceremony themed “Unlocking a New Chapter in China, Led by Purpose, Built on Quality” in Hangzhou, Zhejiang Province.

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders, is pleased to announce that a genetic medicines customer has selected to progress to the final commercial development phase for Optimer delivery vehicles.

This compendium explores analytical advancements in cell and gene therapy, highlighting the latest tools and strategies for ensuring therapeutic quality.